Nerve growth factor

Akston Biosciences' AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Manufacturing, Diabetes, Health, Pharmaceutical, Research, Other Manufacturing, Infectious Diseases, Science, Veterinary, Clinical Trials, MERS, NOD, Atopic dermatitis, Insulin, Immune tolerance, CGMP, Epitope, Mouse, Immunoglobulin G, Chronic pain, Protein, Infection, Vaccination, Immune system, Nerve growth factor, Notifiable disease, Dengue fever, Vaccine

The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).

Key Points: 
  • The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).
  • AKS-107 is a human IgG1 Fc-fusion protein engineered to retain conformational insulin epitopes that bind to B cell receptors while preventing binding to the insulin metabolic receptor.
  • Regarding its Animal Health applications, Akston is partnered with Dechra Pharmaceuticals PLC to commercialize canine and feline ultra-long insulins.
  • Akston Biosciences Corporation is dedicated to accelerating the next revolution in Animal Health by inventing, developing, and manufacturing breakthrough protein therapeutics for veterinary use.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Veterinary, MERS, Dengue fever, Atopic dermatitis, Kinetics, RBD, Vaccination, Immunoglobulin G, Chronic pain, Nerve growth factor, Dementia, Protein, Infection, CGMP, Notifiable disease, Immune system, Vaccine

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.com and Develops Its Next Pre-Workout Formulation

Retrieved on: 
Tuesday, September 5, 2023
Surgeon, Diet, Forest Products Research Laboratory, Wrist, Oxygen, Nerve growth factor, Nutrient, Spine, Hypoesthesia, Nerve block, Cartilage, Research, Genomics, Fungus, Sensation, Movement, Pain, Athlete, Plant, Cordyceps, NASA, OTC, Motorcycle, Injury, Dietary supplement

https://www.amazon.com/dp/B0C9C656KR?ref=myi_title_dp The company is also developing additional sales channels, both online and brick-and-mortar, for the MaxGenomicTM supplements.

Key Points: 
  • https://www.amazon.com/dp/B0C9C656KR?ref=myi_title_dp The company is also developing additional sales channels, both online and brick-and-mortar, for the MaxGenomicTM supplements.
  • This product formulation is based on the same scientific nutritional genomic principles as MaxGenomicTM.
  • Nutritional genomics concerns the relationship between nutrients, diet, and genetic expression, and Pharmagreen products utilize all natural compounds from beneficial/therapeutic fungi and plants.
  • The MaxGenomicTM racing team represented by Ethan (the designated driver) will be racing in ST4MASA Gran Turismo, NASA GR86 series.

Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Retrieved on: 
Friday, May 5, 2023
Medical Supplies, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Pets, Medical Devices, Consumer, Veterinary, Clinical Trials, Exercise, Osteoarthritis, Inc., Blood urea nitrogen, Prevalence, Senior, Veterinarian, Overalls, European Medicines Agency, State university system, Human, Quality of life, Zoetis, Dermatitis, North Carolina State University, EMA, Urinary tract infection, Translational research, Dog, Pain management, Nerve growth factor, NGF, Chronic pain, Regulation of tobacco by the U.S. Food and Drug Administration, BUN, NYSE, Food, Vaccine, Hunting, OA, Pain

Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.
  • Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.
  • The pain of OA can impact a dog’s physical and emotional health.
  • This once monthly injection works differently from other pain medications – it’s unique mode of action targets Nerve Growth Factor (NGF), a key component of OA pain.

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

Retrieved on: 
Tuesday, October 11, 2022
Lewy body, Medical school, Pharmacology, Memorial Sloan Kettering Cancer Center, Cholinesterase, Therapy, University of California, San Diego, Degenerative disease, Pfizer, Private Securities Litigation Reform Act, Vance DeGeneres, Retina, Antibody, Fasinumab, Research, Dementia, Nasdaq, Anesthesiology, Risk, Nerve growth factor, U.S. Securities and Exchange Commission, Department, CEO, Pain, Securities & Exchange Commission of Pakistan, Cognition, Forest Laboratories, Chemistry, DLB, CNS, Temple University, GLOBE, Intellectual property, Chronic pain, Stony Brook University, Eisai, Central nervous system, Regeneron Pharmaceuticals, Bachelor of Science in Human Biology, Pharmaceutical industry, Science, Philosophy

Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.

Key Points: 
  • Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.
  • Dr. Tiseo was most recently the executive director of clinical development at Centrexion Therapeutics, a private biotechnology company focused on the development of non-opioid drugs for the treatment of acute and chronic pain.
  • At Centrexion he worked with the clinical operations and regulatory teams to develop and execute strategies for the clinical development of the companys lead Phase 3 candidate as well as a pipeline of earlier stage therapeutics.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.

Opioid Prescriptions for Noncancer Pain Decrease Yet Other Drugs Increase

Retrieved on: 
Thursday, September 1, 2022
Chronic pain, National, Pain, JAMA Network Open, Nerve growth factor, Mental, Awareness, Solution, Death, Man, City council, Drug, Spine, Board, Physician, Anxiety, Brain-derived neurotrophic factor, Anticonvulsant, Supervisor, Pain scale, Pain management, Prescription, Quality of life, Insomnia, Sympathetic nervous system, Multimedia, Foundation, Depression, Analgesic, Association, Center, Medicare, Antipyretic, Chiropractic, The Harris Poll, Mental health, Korea Disease Control and Prevention Agency, Risk, Woman, Growth, Benzodiazepine, CDC, Agitation, Patient, Birth control, Pharmaceutical industry, Residential care, Health insurance

SAN JOSE, Calif., Sept. 1, 2022 /PRNewswire/ -- During National Drug-Free Pain Management Awareness Month in September, the Foundation for Chiropractic Progress (F4CP) cautions that although opioid prescriptions for noncancer pain are down by one-third in the U.S. since new federal guidelines were enacted, the growth of non-opioid painkiller prescriptions has increased, effectively trading one potentially risky drug for another.

Key Points: 
  • Prescriptions for nonopioid painkillers, including non-steroidal anti-inflammatory drugs, analgesics or antipyretics, anticonvulsants and antidepressants increased by 8% in 2017 and 9.7% in 2018.
  • During the study period, the number of opioid prescriptions decreased by nearly one-third.
  • The prescribing study did not include drugs from the benzodiazepine class, yet prescriptions for these drugs for pain-related complaints have also increased , according to a JAMA Open Network study published in 2019.
  • Mental health conditions, such as depression or anxiety, can exacerbate physical pain and increase the risk of overdose or death.

Global Beta Nerve Growth Factor (Beta NGF or NGF) Drug Development Market Research Report 2022: Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, Pharmaceutical, Health, Molecule, Company, Neuron, Mall of America, NGF, VI, Growth, Proteolysis, Survival, Target, Maintenance, R, Nerve growth factor, Discovery, Therapy, Phosphorus, Pharmaceutical industry

The "Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 14 molecules.
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons.
  • Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects.

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®

Retrieved on: 
Tuesday, February 15, 2022
Amyotrophic lateral sclerosis, NASDAQ, EMA, Orphan drug, Food, European Medicines Agency, Company, California Institute for Regenerative Medicine, Neurodegeneration, California Institute for Quantitative Biosciences, Phrase, NGF, MS, Annual report, IP, Adult, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Cell, NTFS, CIRM, National, FDA, Regenerative medicine, BDNF, Patent, HGF, Research, Hepatocyte growth factor, VEGF, GDNF, Multiple sclerosis, Microsoft, Nerve growth factor, Vaccine, Pharmaceutical industry, Brainstorm, ALS, EU

"We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.

Key Points: 
  • "We are committed to the development of NurOwn as a potential treatment for ALS and other neurodegenerative diseases.
  • This patent, which covers the industrial manufacturing process for NurOwn developed by Brainstorm's scientists, enhances our ability to do so worldwide," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats

Retrieved on: 
Thursday, January 13, 2022
FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Veterinary, Cartilage, DVM, NGF, NYSE, Assistant, Chronic pain, Vomiting, Prevalence, DP, Human, Safety, Overalls, Union, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Inc., Risk, Behavioral medicine, Anaphylaxis, Mab, Doctor of Philosophy, Allergy, Food, Treatment, FDA, Osteoarthritis, Annual report, Woman, Breeding, Forward-looking statement, Vaccine, Inflammation, Liver, Dog, Veterinarian, Nerve growth factor, Solution, Veni, vidi, vici, Farmer, Health, Time, PAW, Livestock, North Carolina State University, Trial of the century, American Veterinary Medical Association, SCI, Antibody, Joint, Synovial fluid, JAE, OA, North Carolina State University College of Veterinary Medicine, Anesthesiology, Dentistry, Poultry, Pharmaceutical industry, Veterinary medicine, Zoetis, Animal, Pain, Solensia™ (frunevetmab injection), Feline Osteoarthritis, Zoetis, SOLENSIA™ (FRUNEVETMAB INJECTION), FELINE OSTEOARTHRITIS, ZOETIS

The approval of Solensia is a significant step forward in the control of feline OA pain.

Key Points: 
  • The approval of Solensia is a significant step forward in the control of feline OA pain.
  • Solensia works differently than other available treatments by targeting Nerve Growth Factor (NGF), a key driver of OA pain.
  • NGF activates and perpetuates the pain signal by increasing the release of additional pain and inflammation mediators.4 By targeting NGF, Solensia reduces pain signals and effectively controls feline OA pain.
  • Solensia is a monoclonal antibody therapy administered in the clinic that targets Nerve Growth Factor (NGF) to control feline OA pain.

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Retrieved on: 
Thursday, January 13, 2022
Research, Medicine, Vaccine, Nerve growth factor, Veterinarian, Animal, Office of Inspector General, U.S. Department of Health and Human Services, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mark (given name), Food, NGF, Diarrhea, Dermatitis, Safety, Center for Veterinary Medicine, Human services, Chronic pain, Joint, Smokeless tobacco, Center, Public health, Dietary supplement, Time, Osteoarthritis, Pain, Skin, Mab, Itch, Quality of life, Head, Neck, Cat, Multimedia, Itchy, Veterinary medicine, Cosmetics, FDA, Brain, Vomiting, China Biologic Products, Generic drug

Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats.

Key Points: 
  • Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats.
  • The two clinical trials were both masked, randomized, controlled field studies involving client-owned cats with clinical signs of osteoarthritis.
  • The cats' veterinarians assessed the cats based on orthopedic examinations before and after treatment.
  • Overall, the cats in the treatment group had better assessment scores than those in the control group.